JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

Inicio・Lista de Acciones・Anavex Life Sciences Corp

Search

Anavex Life Sciences Corp

Abierto

SectorSanidad

3.32 -0.6

Resumen

Variación precio

24h

Actual

Mínimo

3.2800000000000002

Máximo

3.33

Métricas clave
By Trading Economics
Ingresos	4.1M -5.7M
Empleados	34
EBITDA	3.1M -6.8M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+486.51% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-84M 305M
Apertura anterior	3.92
Cierre anterior	3.32

Noticias sobre sentimiento de mercado

By Acuity

17%

83%

36 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.275 / 9.312 Soporte y Resistencia

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 may 2026, 22:17 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 may 2026, 23:47 UTC

Ganancias

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 may 2026, 23:40 UTC

Charlas de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 may 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Shareholders to Own About 51% of Combined Company

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Board Unanimously Endorsed, Supported Deal

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Deal Unanimously Recommended by Vault Board

4 may 2026, 22:39 UTC

Adquisiciones, fusiones, absorciones

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources to Acquire All Ordinary Shares in Vault

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources, Vault Minerals Agree to Merger of Equals

4 may 2026, 22:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 may 2026, 22:26 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 may 2026, 22:02 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 may 2026, 22:00 UTC

Charlas de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 may 2026, 21:52 UTC

Ganancias

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 may 2026, 21:49 UTC

Ganancias

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 may 2026, 21:43 UTC

Ganancias

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 may 2026, 21:41 UTC

Ganancias

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 may 2026, 21:40 UTC

Ganancias

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

486.51% repunte

Estimación a 12 Meses

Media 20 USD 486.51%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

36 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Otras acciones del sector

JNJ

Johnson and Johnson

225.83

UNH

UnitedHealth Group Inc

362.86

TMO

Thermo Fisher Scientific Inc

464.87

ISRG

Intuitive Surgical Inc

449.45

ABT

Abbott Laboratories

87.44

Live chat